|
3.1 Tabac
|
|
|
|
3.1.1 Tabac - e-cigs
|
|
|
|
5. Traitements
|
|
|
|
5.12 Immunothérapies
|
|
|
|
Pfizer bankrolls an oncolytics biotech upstart with an eye on a future buyout [EndPoints]
|
|
|
|
|
|
Pfizer
is also paying for the R&D work at the company over the next three
years, as Ignite looks to jump into a wave of up and coming biotechs
where are hurrying along next-gen oncolytic vaccines aiming at
surpassing the pioneering Imlygic (T-Vec), marketed by Amgen. A bunch of
these startups are pairing up with checkpoint inhibitors, a fact that
wasn’t lost on Pfizer as it seeks the 4th OK of a checkpoint drug.
|
|
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
5.2 Pharma
|
|
|
|
5.2.3 Pharma - économie
|
|
|
Supreme Court declines to hear biologic drug patent fight [Reuters]
|
|
|
|
|
|
The
justices opted not to take up Apotex Inc's appeal of a July federal
appeals court ruling that could delay the Canadian generic drug maker's
launch of so-called biosimilar versions of California-based Amgen Inc's
Neulasta, used to fight infection in cancer patients.
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
Scottish breast cancer patients denied drug approved for English NHS [The Telegraph]
|
|
|
|
|
|
Campaigners
said the Scottish Medicines Consortium’s (SMC) decision not to accept
Perjeta - also known as pertusumab - had created the "ultimate postcode
lottery". The agency, which decides which new drugs should be provided
on the NHS, said it had rejected the treatment over concerns about its
long-term survival benefits and not because of cost.
|
|
|
|
|
|
|
5.7.1 SABCS-communiqués
|
|
|
|
5.7.2 SABCS-divers
|
|
|
|
5.9 AACR
|
|
|
|
6.1 Observation
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
6.6 Publications
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
Watson and Pfizer [In the Pipeline]
|
|
|
|
|
|
From
what I understand, a key feature to any machine-learning approach is
having negative data for it to work with as well as positive (which
makes sense). The problem is, the literature is extremely sparse on
negative results.
|
|
|
|